GlassScriptPhysician profile
Bella Lerman
NPI 1134561616
$3,214.09
in general payments reported to CMS, 2019-2025
27 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $224 · 2021: $485 · 2022: $418 · 2023: $191 · 2024: $585 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $91.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.24 |
| Education | $91.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $688.54 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $546.83 | 2020-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $281.32 | 2024-2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $207.16 | 2024-2025 | Dupixent |
| Kaleo, INC. | $187.87 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $184.97 | 2019-2025 | |
| Covis Pharma Gmbh | $184.44 | 2019-2022 | |
| Genentech USA, INC. | $169.00 | 2022-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $144.97 | 2019-2025 | |
| Pfizer INC. | $109.54 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $92.87 | 2025 | Neffy |
| Optinose US, INC. | $58.51 | 2020-2021 | |
| Pharming Healthcare, INC. | $55.21 | 2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $45.28 | 2025 | Glassia, Cuvitru |
| Phadia US INC. | $26.75 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $26.69 | 2025 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.42 | 2020 | |
| Uswm, LLC | $22.00 | 2021 | |
| Amgen INC. | $21.79 | 2022 | |
| Lilly USA, LLC | $21.38 | 2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $20.64 | 2022 | |
| Shire North American Group INC | $20.52 | 2019 | |
| Leo Pharma INC. | $18.94 | 2022 | |
| Organon LLC | $16.71 | 2025 | |
| Eyevance Pharmaceuticals LLC | $15.15 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.78 | 2021 | |
| Aimmune Therapeutics, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bella Lerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.